Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription 26.05.2025 1 Arch Virol 1 BMC Pediatr 2 BMJ 3 Clin Infect Dis 1 Infect Immun 1 J Infect Dis 1 MMWR Morb Mortal Wkly Rep 1 N Engl J Med 1 Nat Immunol 1 Nat Med 11 PLoS One 33 Vaccine 1 Virology 1 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Virol

1. CHEN T, Xu W, Duan P, Jiang S, et al
   MF59-like adjuvant containing yeast-derived squalene enhances the humoral immune response to cell-derived influenza vaccine.
   Arch Virol. 2025;170:134.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

2. MOHAMMED O, Efua SV, Adjei CA, Darkwa IO, et al
   Uptake of combined immunoprophylaxis for newborns exposed to hepatitis B virus in a high hepatitis B endemic rural setting in Northern Ghana.
   BMC Pediatr. 2025;25:407.
   PubMed         Abstract available
   
   

   
   BMJ

3. WISE J
   Gonorrhoea: England rolls out "world first" vaccination programme.
   BMJ. 2025;389:r1064.
   PubMed        
   
   
4. LOOI MK
   Trump watch: Kennedy stands firm, EPA weakens drinking water protections, and new covid vaccine regulations incoming.
   BMJ. 2025;389:r1032.
   PubMed        
   
   

   
   Clin Infect Dis

5. CHUMAKOV K, Plotkin SA
   Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication.
   Clin Infect Dis. 2025 May 21:ciaf215. doi: 10.1093.
   PubMed        
   
   
6. MEHMOOD N, Alam MM, Arshad Y, Akhtar R, et al
   Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019-2021.
   Clin Infect Dis. 2025 May 21:ciaf151. doi: 10.1093.
   PubMed         Abstract available
   
   
7. KU JH, Gu YM, Hoke CF, Tseng HF, et al
   Screening and vaccination rates for tetanus, hepatitis A, and hepatitis B among individuals with substance use disorders who are hospitalized in an integrated U.S. health system.
   Clin Infect Dis. 2025 May 20:ciaf251. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Infect Immun

8. AZEVEDO JF, Joyner G, Kundu S, Samanta K, et al
   Maternal transfer of oral vaccine induced anti-OspA antibodies protects Peromyscus spp. from tick-transmitted Borrelia burgdorferi.
   Infect Immun. 2025 May 19:e0021625. doi: 10.1128/iai.00216.
   PubMed         Abstract available
   
   

   
   J Infect Dis

9. BAUM HE, Santopaolo M, Francis O, Milodowski EJ, et al
   Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.
   J Infect Dis. 2025 May 20:jiaf246. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   MMWR Morb Mortal Wkly Rep

10. LEBO E, Vynnycky E, Alexander JP Jr, Ferrari MJ, et al
    Estimated Current and Future Congenital Rubella Syndrome Incidence with and Without Rubella Vaccine Introduction - 19 Countries, 2019-2055.
    MMWR Morb Mortal Wkly Rep. 2025;74:305-311.
    PubMed         Abstract available
    
    

    
    N Engl J Med

11. PRASAD V, Makary MA
    An Evidence-Based Approach to Covid-19 Vaccination.
    N Engl J Med. 2025 May 20. doi: 10.1056/NEJMsb2506929.
    PubMed        
    
    

    
    Nat Immunol

12. FENG Y, Pulendran B
    Antibiotics, microbiota and the calibration of infant vaccine responses.
    Nat Immunol. 2025 May 19. doi: 10.1038/s41590-025-02169.
    PubMed        
    
    

    
    Nat Med

13. GARRETSON TA, Liu J, Li SH, Scher G, et al
    Immune history shapes human antibody responses to H5N1 influenza viruses.
    Nat Med. 2025;31:1454-1458.
    PubMed         Abstract available
    
    

    
    PLoS One

14. DORJEE K, Sadoff RC, Mansour FR, Dorjee S, et al
    Menstrual disturbance associated with COVID-19 vaccines: A comprehensive systematic review and meta-analysis.
    PLoS One. 2025;20:e0320162.
    PubMed         Abstract available
    
    
15. PARIDANS M, Dardenne N, Gillain N, Husson E, et al
    Removing barriers to COVID-19 vaccine intention in a university population: Results of a serial mediation study through the dimensions of the Health Belief Model.
    PLoS One. 2025;20:e0322881.
    PubMed         Abstract available
    
    
16. PUCA C, Wood-Kenney P, Nelson N, Hansen J, et al
    "Our kids are our future": Barriers and facilitators to vaccine uptake and timeliness among Aboriginal children younger than five years in Boorloo (Perth), Western Australia.
    PLoS One. 2025;20:e0317946.
    PubMed         Abstract available
    
    
17. JONGKEES MJ, Bogers S, de Vries RD, GeurtsvanKessel CH, et al
    Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: A two-year follow-up study.
    PLoS One. 2025;20:e0323792.
    PubMed         Abstract available
    
    
18. SAMARA KA, Barqawi HJ, Alhayali DM, Kannas SM, et al
    Evaluation of knowledge, attitudes and vaccine hesitancy towards MMR vaccine among parents in the United Arab Emirates.
    PLoS One. 2025;20:e0324629.
    PubMed         Abstract available
    
    
19. WU H, He X, Cao Y, Gao W, et al
    Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis.
    PLoS One. 2025;20:e0310474.
    PubMed         Abstract available
    
    
20. WARD CL, Rojas Castro MY, Chakhunashvili G, Chitadze N, et al
    COVID-19 vaccine effectiveness among healthcare workers during the Omicron period in the country of Georgia, January - June 2022.
    PLoS One. 2025;20:e0311337.
    PubMed         Abstract available
    
    
21. OVER D, Santana E, Amaral EFL, Lakkimsetti C, et al
    A comprehensive analysis of COVID-19 vaccination behavior: The influence of religion, information sources, political leanings, and demographic factors.
    PLoS One. 2025;20:e0323815.
    PubMed         Abstract available
    
    
22. YAN X, Liu Y, Chen F, Chang Z, et al
    The efficacy and effectiveness of enterovirus A71 vaccines against hand, foot, and mouth disease: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0323782.
    PubMed         Abstract available
    
    
23. AJIT J, Chen Q, Ung T, Rosenberger M, et al
    beta-glucan induced trained immunity enhances antibody levels in a vaccination model in mice.
    PLoS One. 2025;20:e0323376.
    PubMed         Abstract available
    
    
24. NOREEN K, Khalid SN, Javaid M, Khan SA, et al
    Public Health Implications of Introducing Human Papillomavirus (HPV) Vaccination in Pakistan: A protocol for a mixed-method study to explore community perceptions and health system preparedness.
    PLoS One. 2025;20:e0323826.
    PubMed         Abstract available
    
    

    
    Vaccine

25. KEUTLER A, Lainka E, Hudert C, Bufler P, et al
    Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study.
    Vaccine. 2025;59:127288.
    PubMed         Abstract available
    
    
26. TIAN X, Zhou Y, Deng P, Xu N, et al
    Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial.
    Vaccine. 2025;59:127268.
    PubMed         Abstract available
    
    
27. QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al
    Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.
    Vaccine. 2025;58:127223.
    PubMed         Abstract available
    
    
28. FITZPATRICK T, Yamoah P, Summerby-Murray D, Cowan J, et al
    Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network.
    Vaccine. 2025;59:127254.
    PubMed         Abstract available
    
    
29. BUSSINK-VOOREND D, Hulscher MEJL, Akkermans R, Krom A, et al
    Vaccine hesitancy among Dutch parents of newborn children and its associated characteristics, values and uptake of vaccines.
    Vaccine. 2025;59:127244.
    PubMed         Abstract available
    
    
30. NHAM E, Song JY, Sohn JW, Choi WS, et al
    Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months.
    Vaccine. 2025;59:127275.
    PubMed         Abstract available
    
    
31. SCHAFFER AL, Hulme WJ, Horne E, Parker EPK, et al
    Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years in England: Regression discontinuity analysis in OpenSAFELY-TPP.
    Vaccine. 2025;59:127257.
    PubMed         Abstract available
    
    
32. MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al
    Guided design for the development of an evolution-proof influenza vaccine.
    Vaccine. 2025;59:127281.
    PubMed         Abstract available
    
    
33. HATTORI F, Higashimoto Y, Miura H, Kawamura Y, et al
    Epidemiology and clinical features of breakthrough varicella in the 9 years after universal vaccination began in Japan.
    Vaccine. 2025;59:127274.
    PubMed         Abstract available
    
    
34. FURUSE Y, Tabuchi T
    Impact of COVID-19 vaccination by implementation timing and coverage rate in relation to misinformation prevalence in Japan.
    Vaccine. 2025;59:127273.
    PubMed         Abstract available
    
    
35. LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al
    DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo.
    Vaccine. 2025;59:127231.
    PubMed         Abstract available
    
    
36. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Routine vaccination rates globally: A continuing and alarming situation.
    Vaccine. 2025;59:127269.
    PubMed        
    
    
37. FINNEY J, Kuraoka M, Song S, Watanabe A, et al
    Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
    Vaccine. 2025;56:127157.
    PubMed         Abstract available
    
    
38. XU P, Lu J, Chen L, Chen X, et al
    Development of a chicken egg yolk antibody (IgY) could effectively prevent and treat goose astrovirus infection.
    Vaccine. 2025;56:127167.
    PubMed         Abstract available
    
    
39. ISLAM MD, Islam MM, Inoue A, Yesmin S, et al
    Neutralizing antibodies against the Japanese encephalitis virus are produced by a 12 kDa E. coli- expressed envelope protein domain III (EDIII) tagged with a solubility-controlling peptide.
    Vaccine. 2025;56:127143.
    PubMed         Abstract available
    
    
40. KISLAYA I, Caserta M, Faye SLB, Dia OK, et al
    Evaluating the effects of a multisectoral dialogue-based COVID-19 awareness-raising intervention in a limited-resource setting: A quasi-experimental study in Senegal.
    Vaccine. 2025;56:127168.
    PubMed         Abstract available
    
    
41. SOARES LMC, de Medonca AEO, de Souza DLB, Carvalho AV, et al
    Factors associated with HPV vaccine hesitancy: A nationally representative cross-sectional study.
    Vaccine. 2025;59:127278.
    PubMed         Abstract available
    
    
42. LUPTON D, Whitten T, Tay AK, Beek K, et al
    Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.
    Vaccine. 2025;58:127251.
    PubMed         Abstract available
    
    
43. NUNEZ IA, Ross TM
    Corrigendum to "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine 38 (4) (2020) 830-839].
    Vaccine. 2025;58:127205.
    PubMed        
    
    
44. AVERIN A, Quinn E, Atwood M, Weycker D, et al
    Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.
    Vaccine. 2025;58:127191.
    PubMed         Abstract available
    
    
45. SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al
    Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
    Vaccine. 2025;58:127267.
    PubMed         Abstract available
    
    
46. NIINIKOSKI V, Barkoff AM, Mertsola J, Holubova J, et al
    Alterations in the expression of Bordetella pertussis antigens in relation to the use of acellular pertussis vaccine in Finland.
    Vaccine. 2025;58:127279.
    PubMed         Abstract available
    
    
47. EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al
    Corrigendum to "Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda" [Vaccine 53 (2025) 127089].
    Vaccine. 2025;58:127204.
    PubMed        
    
    
48. HUNG SH, Torres JL, Chen F, Giang E, et al
    Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.
    Vaccine. 2025;58:127239.
    PubMed         Abstract available
    
    
49. BUHL E, Vedel JO, Nanque LM, Correia C, et al
    Does timing of the Bacillus Calmette-Guerin vaccine affect weight in children under the age of 5 years? An observational study in Guinea-Bissau.
    Vaccine. 2025;58:127246.
    PubMed         Abstract available
    
    
50. SOBLE A, Malhame M, Malvolti S, Mantel C, et al
    Identification and sizing of the current use cases for seasonal influenza vaccines.
    Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233.
    PubMed         Abstract available
    
    
51. MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al
    Childhood vaccine hesitancy: The power of metaphors.
    Vaccine. 2025;58:127221.
    PubMed         Abstract available
    
    
52. PATTYN J, Hanning N, Valckx S, Claessens T, et al
    Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).
    Vaccine. 2025;58:127250.
    PubMed         Abstract available
    
    
53. MERRITT A, Bansal S
    Prison Vaccination in a pandemic: Geographic disparities and policy insights.
    Vaccine. 2025;58:127218.
    PubMed         Abstract available
    
    
54. ELLIS JT, Kennedy PJ
    Multi-criteria decision making and its application to in silico discovery of vaccine candidates for Toxoplasma gondii.
    Vaccine. 2025;58:127242.
    PubMed         Abstract available
    
    
55. GIANNINI F, Hogan AB, Cameron E, Le H, et al
    Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study.
    Vaccine. 2025;56:127155.
    PubMed         Abstract available
    
    
56. MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al
    Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice.
    Vaccine. 2025;56:127203.
    PubMed         Abstract available
    
    
57. WIBOWO DP, Chalid MT, Rasyak MR, El Khobar KE, et al
    Characteristics of hepatitis B virus surface protein and occult hepatitis B infection in infants with immunoprophylaxis failure from Indonesia.
    Vaccine. 2025;56:127130.
    PubMed         Abstract available
    
    

    
    Virology

58. SONI S, Kennedy MA, Wang D, Li F, et al
    The role and implication of rotavirus VP8 * in viral infection and vaccine development.
    Virology. 2025;609:110563.
    PubMed         Abstract available
    
    

    
    Virus Res

59. LI H, Han J, Wang B, Han Z, et al
    Isolation and characterization of GI-19/L1148-like infectious bronchitis virus in China.
    Virus Res. 2025;356:199576.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.